QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPSChina Warehouse
What is Orforglipron?
Orforglipron (Oral non-peptide allosteric GLP-1R agonist) is a Small molecule (MW ~450, non-peptide). First non-peptide GLP-1R agonist approved (2025). Activates GLP-1R via allosteric (not orthosteric) binding — enabling oral bioavailability without peptide backbone. Biased agonism profile differs from peptide GLP-1R agonists. ATTAIN Phase 3: ~14.7% weight reduction at 36 weeks.
Research Applications
Allosteric GLP-1R Agonism
Allosteric vs orthosteric receptor binding comparison research
Oral Bioavailability
No injection stress confound — oral GLP-1R biology in rodent models
Biased Signalling
Small molecule vs peptide GLP-1R agonist downstream bias
Obesity Research
ATTAIN Phase 3 reference — 14.7% weight reduction at 36 weeks
vs Injectable GLP-1R
Mechanism and downstream signalling comparison
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2211316-73-5 |
| Identity | MS molecular weight confirmed — every batch |
| Peptide Type | Small Molecule GLP-1 Receptor Agonist |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months sealed |
